Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC)

Autor:	Takashi Seto, Christian Grohé, Egbert F. Smit, Toyoaki Hida, Lecia V. Sequist, Sang-We Kim, Santiago Ponce Aix, Mariama Diallo, Jinnie Ko, James Chih-Hsin Yang, Enriqueta Felip, Philippe Pultar, Monica Giovannini, Dong Wan Kim, Daniel Shao-Weng Tan, Juergen Wolf
Rok vydání:	2018
Předmět:	Oncology Cancer Research medicine.medical_specialty integumentary system Adult patients business.industry Mutant non-small cell lung cancer (NSCLC) medicine.disease 030226 pharmacology & pharmacy respiratory tract diseases Therapy naive 03 medical and health sciences T790M 0302 clinical medicine Multicenter study Open label study 030220 oncology & carcinogenesis Internal medicine medicine business
Zdroj:	Journal of Clinical Oncology. 36:9094-9094
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.9094
Popis:	9094Background: Nazartinib (EGF816) is a third-generation EGFR-TKI selective for activating and T790M mutations while sparing wild-type EGFR. In the Phase I part of a Phase I/II multicenter study o...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9be23d890bd87d2be886aaf236e4047a https://doi.org/10.1200/jco.2018.36.15_suppl.9094 Zobrazit plný text záznamu